Medpace (MEDP) PT Raised to $625 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts MEDP Hot Sheet
Price: $662.48 +6.43%
Rating Summary:
4 Buy, 16 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
4 Buy, 16 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Medpace (NASDAQ: MEDP) to $625.00 (from $600.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Medpace Holdings (MEDP) Tops Q3 EPS by 40c; offers guidance
- Pegasystems (PEGA) PT Lowered to $43 at Rosenblatt
- Barclays cuts Cirrus Logic price target to $95 from $130, cuts to Underweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
